[Claims]

[Claim 1]

An inhibitor for a retinochoroidal disorder comprising (E)-4-(2-{3-[(1H-pyrazole-1-yl)methyl]-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl}vinyl)benzoic acid, an ester thereof, or a salt thereof as an effective ingredient.

[Claim 2]

The inhibitor for a retinochoroidal disorder of claim 1, wherein the (E)-4-(2-{3-[(1H-pyrazole-1-yl)methyl]-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl}vinyl)benzoic acid, the ester thereof, or the salt thereof is (E)-4-(2-{3-[(1H-pyrazole-1-yl)methyl]-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl}vinyl)benzoic acid or a salt thereof.

[Claim 3]

The inhibitor for a retinochoroidal disorder of claim 1 or 2, wherein the retinochoroidal disorder is formation or atrophy of a retinochoroidal scar in subretinal, intraretinal, or epiretinal tissue.

[Claim 4]

The inhibitor for a retinochoroidal disorder according to any one of claims 1-3, wherein a form of administration is instillative administration or oral administration.

[Claim 5]

The inhibitor for a retinochoroidal disorder accordingly to any one of claims 1-4, wherein a dosage form is an instillation, an ophthalmic ointment, an injection, a tablet, a granule, a fine granule, a powder or a capsule.

[Claims]

[Claim 1]

An inhibitor for a retinochoroidal disorder comprising (E)-4-(2-{3-[(1H-pyrazole-1-yl)methyl]-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl}vinyl)benzoic acid, an ester thereof, or a salt thereof as an effective ingredient.

[Claim 2]

The inhibitor for a retinochoroidal disorder of claim 1, wherein the (E)-4-(2-{3-[(1H-pyrazole-1-yl)methyl]-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl}vinyl)benzoic acid, the ester thereof, or the salt thereof is (E)-4-(2-{3-[(1H-pyrazole-1-yl)methyl]-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl}vinyl)benzoic acid or a salt thereof.

[Claim 3]

The inhibitor for a retinochoroidal disorder of claim 1 or 2, wherein the retinochoroidal disorder is formation or atrophy of a retinochoroidal scar in subretinal, intraretinal, or epiretinal tissue.

[Claim 4]

The inhibitor for a retinochoroidal disorder according to any one of claims 1-3, wherein a form of administration is instillative administration or oral administration.

[Claim 5]

The inhibitor for a retinochoroidal disorder accordingly to any one of claims 1-4, wherein a dosage form is an instillation, an ophthalmic ointment, an injection, a tablet, a granule, a fine granule, a powder or a capsule.